Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
Department of Public Health and Maternal Child Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
Pharmacoepidemiol Drug Saf. 2020 May;29(5):605-608. doi: 10.1002/pds.5000. Epub 2020 Apr 8.
There is an increase interest on the potential chemoprotective effect of selective phosphodiesterase 5 (PDE5) inhibitors. Several authors have shown in vivo the immune-mediated anti-tumor effect of these inhibitors on tumors arising from the digestive tract.
To test the potential effect of selective PDE5 inhibitors against colorectal cancer (CRC) onset previously observed.
We used data from The Health Improvement Network database and identified an established cohort of 200 000 new users of low-dose aspirin and a matched comparison cohort aged 40-84 years between 1 January 2000 and 31 December 2011. A follow-up to identify CRC cases was performed within an extensive validation exercise. Nested case-control analyses compared PDE5 inhibitors vs non-use on CRC risk were performed.
Restricting to males (59.3% controls and 59.5% cases), no association was observed among current users of PDE5 inhibitors (1.05 [95% CI: 0.69-1.60]) and neither among recent (1.36 [95% CI: 0.81-2.28]) or past users (1.06 [95% CI: 0.72-1.58]). No duration response effect was found.
Our results do not support an increased risk of CRC associated with the use of PDE5 inhibitors among men with erectile dysfunction.
选择性磷酸二酯酶 5（PDE5）抑制剂的潜在化学预防作用引起了人们越来越多的关注。一些作者已经在体内观察到这些抑制剂对来自消化道的肿瘤的免疫介导的抗肿瘤作用。
检验选择性 PDE5 抑制剂对先前观察到的结直肠癌（CRC）发病的潜在影响。
我们使用了来自健康改善网络数据库的数据，确定了一个由 20 万名低剂量阿司匹林新使用者组成的既定队列，以及一个年龄在 40-84 岁之间的匹配对照队列，时间范围为 2000 年 1 月 1 日至 2011 年 12 月 31 日。为了在广泛的验证工作中确定 CRC 病例，我们进行了随访。嵌套病例对照分析比较了 PDE5 抑制剂与非使用者的 CRC 风险。
在男性中（59.3%的对照组和 59.5%的病例组），当前 PDE5 抑制剂使用者（1.05 [95%CI：0.69-1.60]）之间，以及近期（1.36 [95%CI：0.81-2.28]）或过去使用者（1.06 [95%CI：0.72-1.58]）之间均未观察到相关性。也未发现持续时间反应效应。
我们的结果不支持勃起功能障碍男性使用 PDE5 抑制剂与 CRC 风险增加之间存在关联。
Zotero 插件